Autopsy report · NCT01994291
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
Cause of deathNo reason given
Life of this trial
- Ran for about 1 year 9 months before it stopped.
- 199 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Macular Edema, Diabetic
- Interventions
- Ranibizumab; Placebo; PF-04634817; Masked Sham Therapy
- Participants
- 199
- Sites
- 63
- Countries
- Bulgaria, Czechia, Germany, Hungary, Israel, Moldova, Poland, Romania, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.